anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: method involves per os administering riboxin to a patient at a dose of 0.2 g 3 times a day after removing tumor during 5-10 days. Radiation therapy is started at the same time with chemotherapy and brought to total dose of 42-54 Gr on the background of intravenous administration and later on per os administration of riboxin and proxiphein. Riboxin is intravenously injected at a dose of 10 ml during the first two weeks and then per os at a dose of 0.2 g three times a day up to 3 months long. Proxiphein is administered according to the following scheme. 2 days the dose is 0.25 g once a day, two days 0.25 g twice a day, and then, the dose is 0.25 g three times a day during 40-45 days. Chemotherapy course is repeated 4-5 weeks later. Benzonal is applied as anticonvulsive preparation at a dose of 0.1 g or finlepsin at a dose of 0.2 g 3 times a day during the first two weeks and then two times a day to the end of the chemotherapy course and later at a dose of 1 tablet before going to bed not less than 2-3 years long. EFFECT: enhanced effectiveness of treatment.
FIELD: medicine, neurology. SUBSTANCE: biological effect of glucocorticoids is determined preliminary based on the formula describing interrelationship of segmentated leukocytes and contractile capacity of myocardium with glucocorticoid activity. Therapy with prednisolone is carried out at the dose 0.5-1.0 mg/kg body mass. Hyperbaric oxygenation seances were carried out from 1-3 days of treatment and hyperpressure value (from 0.2 to 1.0 ati) is taken on the basis of dynamic control over biological effect of glucocorticoids. At enhanced expression of the latter the dose of exogenous glucocorticoids is decreased or even ceased. EFFECT: enhanced effectiveness of immunocorrective therapy, decreased by-side effect of hormonal preparations and complications.
The invention concerns a new mutant of .gamma.-IFN. This new polypep-tide contains 134 amino acids. Amino acids 1 to 132 are the same as those of natural .gamma.-interferon. The first amino acid, methionine, in the zero posi-tion is also present, as has been demonstrated by protein sequencing. The amino acid in position 133 is leucine instead of glutamine. The invention also concerns DNA sequences and plasmid DNA (DSM 6238) which codes for this new polypeptide. The invention further concerns the use of the polypeptide as a drug as well as its use as a fine-chemical reagent for in vitro experiments.
In the dose escalation of the study, starting with the dose of injection of 5x10\^9. If there is no DLT, followed by the second dose of 1.0x10\^10 until the third dose of 2.0x10\^10.
The invention relates to a prescription of modified zinc oxide with vinegar-soaked mashed garlic for onychomycosis treatment, belonging to the new technical field of intercross and interpenetration between inorganic non-metallic materials and medical preparation science. Firstly nontoxic and flavorless modified zinc oxide which has the functions of astringent, anti-inflammation, antisepsis, fungi elimination and protection of the skin is used. The antibacterial powder of the modified zinc oxide is introduced in vinegar-soaked mashed garlic to improve the treatment effect, and enhance the growth of affected parts, reduce pain, and shorten treatment duration and times. In addition, sesame oil is used for advancing cell division, removing rot muscle, relieving internal fever and preserving moisture. The modified zinc oxide is prepared by zinc acetate as a raw material and ammonium citrate tribasic as a modifier through a sol-gel method. The prescription of modified zinc oxide with vinegar-soaked mashed garlic comprises 50-200g of fresh garlic, 50-150ml of vinegar, 2-5g of modified zinc oxide, and 0.5-1mL of sesame oil. The prescription of modified zinc oxide with vinegar-soaked mashed garlic is used for treating onychomycosis, which is laid on the affected part and coated with an adhesive tape. After 5-7 days for a cycle, the package is opened and the affected part is cleaned, the softened onychomycosis is wiped off by a knife, the same step is cycled until the onychomycosis is basically removed. In general, three cycles are required for treatment.
PROBLEM TO BE SOLVED: To automatically reflect a changed content in the other device when a parameter is changed in one device among a plurality of picture output devices which are network-connected. SOLUTION: Transfer destination specification information are registered in registration means 26, 36 and 46. When a parameter is changed in a picture output device 20, transfer destination specification information registered in the registration means 26 is referred to and the other storage device to which information is to be transferred is specified. Flag information showing the specified device and the changed parameter are outputted to a network line through a transfer means 22. A picture output device 30 receives flag information and the changed parameter by a reception means 31 and stores them in a storage device 34. The parameter is read from the storage device 34 and it is inputted to a picture processing means 35 as the changed parameter P32 of the pertinent device.  The picture processing means 35 selectively uses the existing parameter P31 and the changed parameter P32 and a picture processing is executed on picture data D30 which is read form the storage device 34.
The invention belongs to the technical field of biological medicines, and discloses siRNA for inhibiting the expression of a helicase V gene and application thereof. The siRNA comprises siRNA-2 and/or siRNA-3; the nucleotide sequences of the sense strand and the antisense strand in the siRNA-2 are shown as SEQ ID NO. 3-4; the nucleotide sequences of the sense strand and the antisense strand in the siRNA-3 are shown in SEQ ID NO. 5-6. The siRNA has the performance of interfering and inhibiting the expression of the helicase V gene, can inhibit the proliferation of neurogenic tumor cells such as neuroblastoma and the like, and can promote the apoptosis of the neurogenic tumor cells. The siRNA can be applied to preparing an uncoiling enzyme V gene expression inhibitor, a medicament for promoting tumor cell apoptosis and a medicament for inhibiting tumor cell clone formation.
FIELD: medicine, pharmacology. SUBSTANCE: medicinal agent is prepared by drying rhizome, stems, leaves and flowers of primrose plants (Cyclamen ibericum). Plant parts were milled up to powder state and biologically active substances from the vegetable raw were extracted with water at 85-100 C at ratio raw : extract = 0.7:(1-500) mas. p. p., respectively. Mixture is infused at natural cooling to environment temperature. EFFECT: simplified method of preparing, increased economy, broad spectrum of pharmacological effect.
Following the efficacy assessment method outlined in the 2020 EPOS guidelines, the treatment outcomes of chronic sinusitis are categorized as "controlled" or "uncontrolled." Clinical reference evaluation criteria include: nasal congestion, rhinorrhea, facial pain, reduced sense of smell, sleep disturbances, the need for ongoing medication maintenance and the abnormal nasal endoscopy findings, .If there are no three or more symptoms rated five or higher, the patient's chronic sinusitis is considered controlled.
Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses what was previously termed non-alcoholic fatty liver disease (NAFLD), which is now called metabolic dysfunction-associated steatotic liver disease (MASLD). Additionally, steatotic liver disease includes alcohol-related liver disease (ALD) and MetALD, the new classification for the overlap between MASLD and ALD, and rare causes of liver steatosis. Cirrhosis is globally the 11th leading cause of death, and steatotic liver disease has become the leading cause of cirrhosis in the EU and USA. Steatotic liver disease affects around 30% of the global population and is mainly driven by obesity, type 2 diabetes, and alcohol intake, but only a minor proportion with steatotic liver disease progress to cirrhosis. The presence and progression of liver fibrosis led by hepatic inflammation is the main predictor of liver-related death across the entire spectrum of steatotic liver diseases. A combination of recent advancements of widely available biomarkers for early detection of liver fibrosis together with considerable advancements in therapeutic interventions offer the possibility to reduce morbidity and mortality in patients with steatotic liver disease. This Seminar covers the recent reclassification of steatotic liver disease and how it reflects clinical practice and prognosis. For early detection of liver fibrosis, we propose a collaborative diagnostic framework between primary care and liver specialists. Lastly, we discuss current best practices for managing steatotic liver disease, we explore therapeutic targets across the spectrum of steatotic liver diseases, and we review the pipeline of drugs in development for MASLD.
Purpose: The "Total Mesorectal Excision" (TME) is the standard surgical technique for the treatment of rectal cancer. Up to 50% of sexual dysfunction is described after TME and up to 30% of urinary dysfunction. Although there are other factors, the main cause of postoperative genitourinary dysfunction is intraoperative injury of the autonomic pelvic nerves. One of the regions with more risk is the Inferior Mesenteric Artery (IMA). The main objective of the study is to compare pre- and post-TME sexual dysfunction according to the approach of the inferior mesenteric vessels, directly on the IMA or from the inferior mesenteric vein (IMV) to the IMA.

Methods: Multicenter, prospective, controlled and randomized study of patients with rectal adenocarcinoma with neoadjuvant chemoradiotherapy, who will be randomized into two groups depending on the approach of the inferior mesenteric vessels. The main variable is pre and postoperative sexual dysfunction. The secondary variables are visualization and preservation of the pelvic autonomic nerves, pre- and postoperative urinary dysfunction, pre and postoperative quality of life. The sample to be included will be 90 patients, 45 per group.
NEW MATERIAL:A penicillin derivative of formula I (n is 0,1 or 2), salt and ester hydrolyzable in the living body. EXAMPLE:Benzhydryl 2beta-azidomethyl-2alpha-methylpenam-3alpha-carboxylate. USE:Inhibitors against beta-lactamases. PROCESS:A penicillanic acid derivative of formula II (X is chlorine or bromine; R is a protecting group of the carboxyl group in the penicillin), e.g. benzhydryl 2beta-chloromethyl-2alpha-methylpenam-3alpha-carboxylate, is reacted with a metallic azide, e.g. sodium azide, in an amount of preferably 1-10 times of the molar equivalent of the penicillanic acid derivative of formula II in a solvent, e.g. dimethylformamide, usually at 0-60 deg.C. The reaction mixture is if necessary subjected to the oxidation, ester elimination, ester interchange and salt forming reactions to give the aimed compound of formula I .
Patients will receive a pulmonary rehabilitation program (PRP) supplemented with pulsed electromagnetic field therapy. The latter will be applied for 5 weeks, a total of 3 sessions per week. The BTL-6000 Super Inductive System (SIS) will be used with the 'focus field' type manual applicator. The parameters will be: intensity of the magnetic field up to 2.5 Tesla (T), the frequency range to achieve the analgesic effect will vary between 10-20 Hz and, finally, an adjustable relative intensity up to 100%, depending on the perception subjective of the patients. Sessions will last 10 minutes. The parameters and procedure of therapy follow the manufacturer's recommendations. The SIS will be applied in the area where the patient presents the highest level of pain.
Advise patients to hydrate adequately before, during, and after the use of MoviPrep. If a patient develops significant vomiting or signs of dehydration after taking MoviPrep, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN).

Bowel preparations can cause fluid and electrolyte disturbances, which can lead to serious adverse reactions including cardiac arrhythmias, seizures, and renal impairment [see Adverse Reactions (6.2)]. Correct fluid and electrolyte abnormalities before treatment with MoviPrep. MoviPrep should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities [such as diuretics, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)] or in patients with known or suspected hyponatremia. Consider performing pre-dose and post-colonoscopy laboratory tests (sodium, potassium, calcium, creatinine, and BUN) in these patients [see Drug Interactions (7.1)].
The IMbrave150 study has demonstrated a new regimen to be superior to sorafenib by reducing 42% of death risk, making "T+A" strategy to be the first-line treatment for patients with advanced HCC. Meanwhile, the RESCUE research showed that combined camrelizumab with apatinib has promising objective response rate (ORR=34.3%) and disease control rate (DCR=77.1%) in advanced HCC patients as first-line treatment. Nevertheless, the above researches both show only a fraction of patients benefits from the anti-PD-1/PD-L1 in combination with antiangiogenic therapy. Therefore, it's urgently needed to explore better combinational strategies with other treatments to enhance the efficacy of anti-PD-1 in combination with antiangiogenic therapy. Recently, Pembrolizumab plus allogeneic NK cells have been proved to be effective in advanced non-small cell lung cancer patients. However, there is no study available now analyzing the efficacy and safety of Camrelizumab in combination with apatinib plus NK cell in patients with advanced hepatocellular carcinoma.
PURPOSE:To provide the titled preparation containing a slow-releasing bredinin component coated with enteric or semipermeable coating material, useful as a carcinostatic agent, and having long-acting activity and reduced side effects. CONSTITUTION:The objective drug preparation contains bredinin as an active component in the form of a slow-releasing component. The slow-releasing bredinin is obtained by coating 1pt.wt. of bredinin with 0.1-2pts.wt. of a substance which dissolves in the intestines or exhibits semipermeable property in the body (e.g. copolymer of methacrylic acid and methacrylic acid ester). When a rapidly soluble bredinin component is used in combination with the slow-releasing bredinin component at a weight ratio of 20-60:80-40, the initial concentration of bredinin in the blood can be adequately controlled, and the concentration in the blood can be maintained at a constant level.
Influenza is an important cause of morbidity and mortality among both children and adults. Influenza A and/or B viruses cause yearly epidemics in the United States with an average of 36,000 deaths and 114,000 hospitalizations annually. Children have the highest rates of infection. Influenza is also associated with substantial numbers of hospitalizations among young infants. Because of the limited data available and the variability of reported seroresponses to doses of 0.25 ml in children 6-35 months of age, investigators hypothesize that a higher dose will be more consistently immunogenic. In addition, since currently licensed trivalent inactivated influenza (TIV) vaccines are well tolerated with minimal systemic and local adverse events, investigators hypothesize that administering a higher dose of 0.5 ml to this age group will be well-tolerated. Therefore, investigators propose to compare the safety and immunogenicity of 0.25 ml doses of TIV to that of 0.5 ml doses of TIV when administered to children 6-35 months of age. The proposed study is a phase I, two-arm, 1:2 randomized, double-blinded trial comparing the safety and immunogenicity of increased dose(s) (0.5 ml) with standard dose (0.25 ml) of TIV in children 6-35 months of age with and without a history of previous TIV vaccination. The population will include a Naïve Cohort: 270 healthy male and female children who are 6-35 months of age and have never received an influenza vaccination; and a Fully Primed Cohort: 60 healthy male and female children who are 12-35 months of age and have received two doses of 2009-2010 H1N1 and two doses of TIV at anytime in the past as defined for purposes of this study. Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of TIV will be administered intramuscularly in the anterolateral thigh with a 25 gauge 1" needle. The primary objective is to evaluate the safety of administering an increased dose(s) (0.5 ml) of TIV to children 6-35 months of age as compared to standard dose(s) (0.25 ml) of TIV. The secondary objective is to compare the humoral immune responses to TIV antigens in children 6-35 months of age who receive the increased dose(s) of TIV to those who receive the standard dose(s) of TIV.
This group will receive treatment as usual for 6 weeks. After the completing the 6-week surveys, the waitlist group will receive a subscription to the Headspace app.
Participants will receive 60 seconds of manual pressure applied to one point in their neck followed by 30 seconds of complete pressure release 4 times for a total contact time of 240 seconds. Pressure will be applied such that the participant rates the pain = 5/10 on an 11-point numeric pain rating scale with 0 indicating no pain and 10 indicating the most severe pain imaginable.
There are papers about follicle dimensions and volumes studying their effect on embryologic parameters. But most of these studies are far from practical approach and are not easily applicable, such as 3D volumetric measurement is not feasible for most of the clinics. Also one of the points important for us it to evaluate the duration of the procedure and the possible positive effect of shortening the duration for better results. Investigators plan to measure the follicles just before puncture and arrange two groups. Group 1,follicles with diameter of 17 mm and more, and group 2 follicles between14-17 mm. Maturation, fertilization, cleavage characteristics are recorded. The source of chosen transfer embryo and crio-preserved embryos per cycle is also point of interest.
Patients receive nivolumab IV over 30 minutes on day 1 and BMS-986016 (relatlimab) over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo ECHO during screening as clinically indicated. Patients undergo a biopsy during screening and blood sample collection during screening and on study.
Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of Xylocaine Injection for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated. 

There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Xylocaine is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION). 

These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient. In all cases the lowest concentration and smallest dose that will produce the desired result should be given. Dosages should be reduced for children and for the elderly and debilitated patients and patients with cardiac and/or liver disease. 

The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Thus, an increase in volume and concentration of Xylocaine Injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia. However, increasing the volume and concentration of Xylocaine Injection may result in a more profound fall in blood pressure when used in epidural anesthesia. 

Although the incidence of side effects with lidocaine HCl is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected. 

For intravenous regional anesthesia, only the 50 mL single dose vial containing Xylocaine (lidocaine HCl) 0.5% Injection should be used.
The obesity epidemic is a major public health concern with a significant economic burden in the USA. Bariatric surgery is the most effective and durable weight loss treatment, with long-term cardiometabolic health benefits. Among different types of bariatric procedures, sleeve gastrectomy (SG) has become the most commonly performed in USA. While SG is expected to result in a 50-60% excess weight loss, inter-individual differences in weight loss are large and approximately 25% of patients can be considered poor weight-loss responders who either do not lose a substantial amount of weight or regain the lost weight afterwards. The mechanisms underlying this clinical variation remain unknown and interventions to improve on these outcomes critically lacking. Of interest, altered daily dietary habits are experienced by a substantial proportion of bariatric surgery candidates, raising the question whether such alterations may contribute to inter-individual differences in weight loss success. Therefore, the purpose of the study is to compare dietary habits after bariatric surgery in patients with different weight loss outcomes.
Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
At the time of recruitment, subjects will be asked to indicate whether they would like to participate in a one-time survey, or are willing to participate in the initial survey plus two additional questionnaire administrations, thereafter, which will be used to develop the disease-specific quality of life (QOL) score. All participants will complete either the SF-36 survey (for adult HME subjects) or the CHQ PF (for parents of children with HME), as applicable, in addition to a blank form with categorical subheadings (such as recreation, social function, etc.), which they will use to address any issues not covered in the standardized questionnaire. Standardized questionnaires will be scored and analyzed. The items listed on the second form will be compiled and reapplied to subjects that indicated interest in extended participation in survey completion. Subjects will be asked to determine which items apply to them and to rank these applicable items in order of importance. The results from this will be used to develop a 30 question, disease-specific questionnaire. The final step will be to readminister this survey, in conjunction with the SF-36 or CHQ PF, and follow up, in two weeks, with a second administration of the aforementioned surveys, in order to test the variability and validity of the disease-specific, health-related, quality of life score.